SecBot SecBot
144 ·Filed Jun 26, 2026

KYMR

Kymera Therapeutics, Inc.
BEARISH
Impact 6/10
Horizondays Processed4mo ago SEC0001628280-26-045808
Actionable Insight ▼ Bearish

The paired filings confirm a coordinated, aggressive sell-down by a founding venture investor after a significant stock run (KYMR at ~$9.4B cap with 93% analyst buy rating). Institutional holders should watch for continued secondary distribution, these filings are 'intent to sell' notices, and the trailing realized sales suggest the selling is already underway. The concentration risk from a top holder reducing positions suggests near-term overhang; traders may consider reducing exposure or hedging until the distribution cadence slows.

DirectionBearish
Confidencehigh
Horizondays

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$109.32
T+0 close · Jun 26, 2026 · via day close
Latest settled
+11.65%
T+60 · $122.06
Vs SPY
+7.27%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 29 $109.32entry
  2. T+1 · 5mo ago +4.89%α +4.12% · $114.67
  3. T+5 · 4mo ago +4.98%α +3.59% · $114.76
  4. T+20 · 4mo ago +1.14%α +1.42% · $110.57
  5. T+60 · 8w ago +11.65%α +7.27% · $122.06
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. filed paired Form 144 notices on June 26, 2026, signaling intent to sell a combined 467,878 shares of Kymera Therapeutics common stock worth approximately $54.8 million. The filings reveal a coordinated sell-down by a founding venture capital investor alongside an Atlas-affiliated individual (Bruce Booth), with substantial prior sales executed over the preceding week (June 17–25) totaling ~1.1M shares.

Key Facts

  • Atlas Venture Fund X, L.P. filed Form 144 to sell 410,427 shares valued at ~$47.8 million.
  • Atlas Venture Opportunity Fund I, L.P. filed Form 144 to sell 57,451 shares valued at ~$6.7 million.
  • Combined proposed sale: 467,878 shares worth approximately $54.8 million based on filing price.
  • Atlas entities had already sold ~1,058,130 shares in the prior week (June 17–25) for ~$117.2 million, based on transaction detail reported in the filings.
  • Bruce Booth, an Atlas-affiliated individual, also participated in prior-week sales of 23,900 shares (approx. $2.2 million).
  • Shares were acquired via private placement in March 2020 pre-IPO, representing control/restricted securities.
  • The filers are a top-2 institutional holder (Baker Bros. and Avoro Capital are also top holders per 13F data), making this a material reduction by a founding investor.
  • Recent 30-day insider activity already showed $10M in sales prior to these filings.
  • Market cap of ~$9.4B makes the proposed ~$55M sale ~0.6% of market cap, but the trailing week's realized sales of ~$117M represent ~1.2%.
  • Atlas Venture Fund X alone previously sold ~1,038,500 shares in the prior week, signaling aggressive distribution.

Financial Impact

Proposed sales of ~$54.8M, with trailing week realized sales of ~$117M, bringing total disclosed near-term Atlas distribution to ~$172M. This represents meaningful insider liquidation by a founding venture backer.

dilution (secondary sales)insider sentimentsupply overhang

Risk Factors

  • Continued secondary selling by other insiders or early investors following Atlas's lead.
  • Supply overhang from the ~$55M proposed sale, which could pressure near-term price action.
  • Atlas is a high-conviction early investor, their liquidation may signal a peak valuation view or portfolio rebalancing, but could also be fund-cycle driven.
  • Potential for additional Form 144 filings as Atlas continues its distribution.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
93% bullish (30 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (KYMR), Batch item 10001628280-26-045808
Document: 0001628280-26-045808-index.html0001628280-26-045807
Document: 0001628280-26-045808.txt0001628280-26-045808
144 Filing (KYMR), Batch item 40001628280-26-045807
Document: 0001628280-26-045807-index.html0001628280-26-045808
Document: 0001628280-26-045807.txt0001628280-26-045808

Track record

37 reports on KYMR

Performance horizon

7 of 11 bullish or bearish reports moved the stock their way by T+20. Best: +60.99% at T+60 after the Jun 8, 2026 report. 9 of 13 went positive at some point.

Filters
  1. Nov 2, 202614d ago Institutional Cluster Neutral 3/10 Entry $127.09 Now $125.85 −0.98% settles Dec 2
  2. Oct 29, 202618d ago 8-K Neutral 5/10 No price data
  3. Oct 29, 202618d ago Press Release Bearish 5/10 Entry $122.60 Now $125.85 −2.65% settles Nov 27
  4. Oct 28, 202619d ago Press Release Neutral 5/10 Entry $122.60 Now $125.85 +2.65% settles Nov 27
  5. Oct 27, 202620d ago Institutional Cluster Bullish 4/10 Entry $122.51 Now $125.85 +2.73% settles Nov 25
  6. Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $122.51 Now $125.85 +2.73% settles Nov 25
  7. Oct 22, 202625d ago Press Release Neutral 1/10 Entry $110.85 Now $125.85 +13.53% settles Nov 20
  8. Aug 5, 202614w ago 8-K Bullish 6/10 Entry $105.48 to $118.63 Now $125.85 +19.31% ▲ +12.47% +13.07% vs SPY
  9. Jul 7, 202618w ago Insider Cluster Bearish 5/10 Entry $114.16 to $105.48 Now $125.85 −10.24% ▲ +7.60% +10.88% vs SPY
  10. Jul 2, 202619w ago Insider Cluster Bearish 5/10 Entry $114.76 to $100.31 Now $125.85 −9.66% ▲ +12.59% +13.44% vs SPY
Showing 10 of 37

US Market Status

Market Closed · Opens in 8h 44m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 3, 2026